A prognostic eight‐lncRNA expression signature in predicting recurrence of ER‐positive breast cancer receiving endocrine therapy

Abstract

Long noncoding RNAs (lncRNAs) have the main role in the tumorigenesis of breast cancer. In the present study, lncRNA expression profiling was collected to identify a lncRNA expression signature from the Gene Expression Omnibus database. An eight-lncRNA signature was established to predict the survival of patients with estrogen receptor (ER)-positive breast cancer receiving endocrine therapy. Patients were separated into a low-risk group and a high-risk group based on this signature. Patients in high-risk group have worse survival compared to those in low-risk group using Kaplan-Meier curve analysis with log-rank test. Receiver operating characteristic analysis suggested good diagnostic efficiency of the eight-lncRNA signature. When adjusting the clinical features, including age, grade, lymph node status, and tumor size, this signature was independently associated with the relapse-free survival. The prognostic value of the lncRNA prognostic model was then validated in validation sets. When validated in a cohort of patients treated with neoadjuvant chemotherapy and endocrine therapy, this signature demonstrated good performance as well. Besides, we have built a nomogram that integrated the conventional clinicopathological features and the eight-lncRNA-based signature. To sum up, our results indicated that the eight-lncRNA prognostic model was a reliable tool to group patients at high and low risk of disease relapse. This signature may have possible implication in prognostic evaluations of patients with ER-positive breast cancer receiving endocrine therapy. K E Y W O R D S breast cancer, lncRNA, nomogram, prognosis

Identification of pyroptosis‐related lncRNAs for constructing a prognostic model and their correlation with immune infiltration in breast cancer

“…17 In 2020, Tang et al also manufactured a signature consisting of 8 lncRNAs for ER-BC-positive analysis, which could predict survival in patients receiving endocrine therapy. 18 Thus, it could conclude that ncRNAs, represented by lncRNAs, had the immeasurable potential of prognostic value and ability in BC. More importantly, Ye et al constructed a prognostic signature composed of 7 pyroptosis-related mRNAs in 2021.…”

Connecting the Missing Dots: ncRNAs as Critical Regulators of Therapeutic Susceptibility in Breast Cancer

“…For instance, Wang et al identified an 11-lncRNAs-based signature that could predict longer RSF in ER-positive BC patients treated with tamoxifen [204]. On the other hand, Tang et al developed a lncRNA signature indicative of recurrence in ER-positive BC patients receiving endocrine therapy [254]. Jiang and colleagues also discovered an mRNA-lncRNA signature able to subdivide TNBC patients into groups with high or low risk of relapse.…”

A Potential Nine-lncRNAs Signature Identification and Nomogram Diagnostic Model Establishment for Papillary Thyroid Cancer

“…Development of omics technology has contributed to the diagnosis and treatment of cancers in a systematic approach [ 21 ]. Recently, a method that commonly utilized microarray data for the express profiling of lncRNAs has been well-constructed, which might advance the therapeutic measures for human cancers [ 22 , 23 ]. A unique prognostic nomogram has been established based on the five-lncRNAs signature in clear cell renal cell carcinoma [ 24 ].…”